Sugi Predict

Sugi Predict / Compounds / SCHEMBL873787

SCHEMBL873787

SCHEMBL873787

CC(C)(C)OC(=O)N[C@H](C(=O)O)C(C)(C)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CTSK P43235 10/20 0.41
▸ CTSS P25774 7/20 0.41
▸ CYP2D6 P10635 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ TSHR P16473 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206502 1.00 CA1 (0.44) CA1CA2CA7MEN1GAA
SCHEMBL873398 1.00 CA1 (0.44) CA1CA2CA7MEN1GAA
SCHEMBL90052 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL83699 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL57432 0.86 CA2 (0.50) CA1CA2CA7MEN1GAA
SCHEMBL193767 0.83 MEN1 (0.31) MEN1GAAKMT2ATSHR
SCHEMBL193766 0.83 MEN1 (0.31) MEN1GAAKMT2ATSHR
SCHEMBL23722683 0.82 CA1 (0.43) CA1CA2CA7MEN1GAA
SCHEMBL3805811 0.82 CTSK (0.44) CA1CA2CA7MEN1GAA
SCHEMBL21746358 0.82 CA1 (0.43) CA1CA2CA7MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255695-B Purification method and preparation method of intermediate of beta-lactam compound 广州艾奇西医药科技有限公司 2025-03-14 — — CN claimed
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 — — CN claimed
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
US-12612420-B2 Arginase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2026-04-28 — — US disclosed
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 — — US disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2025-10-02 — — US disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 — — US disclosed
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2025-05-22 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
CN-1018824-B Process for preparing 4, 4-dialkyl-2-azetidinones SQUIBB & SONS INC (US) 1992-10-28 — — CN disclosed
CN-1014894-B Process for preparing 4, 4-dialkyl-2-azetidinones SQUIBB & SONS INC (US) 1991-11-27 — — CN disclosed
CN-1055736-A 4, the preparation method of 4-dialkyl group-2-azetidinones SQUIBB & SONS INC (US) 1991-10-30 — — CN disclosed
EP-0229012-B1 MONOSULFACTAMS E.R. Squibb & Sons, Inc. (US) 1991-06-12 — — EP disclosed
US-4812564-A Process for preparing 4,4-dialkyl-2-azetidinones utilizing a pyridine (or substituted pyridine) sulfur trioxide complex E. R. SQUIBB & SONS, INC. (US) 1989-03-14 — — US disclosed
US-4694083-A Certain carbamate ester derivatives forming salts with pyridinium or picolinium cations which are useful as intermediates E. R. SQUIBB & SONS, INC. (US) 1987-09-15 — — US disclosed
US-4684722-A ANTIBIOTICS E. R. SQUIBB & SONS, INC. (US) 1987-08-04 — — US disclosed
EP-0229012-A1 Monosulfactams E.R. Squibb & Sons, Inc. (US) 1987-07-15 — — EP disclosed
US-4638061-A [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate E. R. SQUIBB & SONS, INC. (US) 1987-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 CA1 3605/4885CA2 2852/4885CA7 1366/4885
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CA1 4882/4885CA2 4875/4885CA7 4861/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 CA1 2824/4885CA2 1024/4885CA7 1184/4885
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 CA1 4521/4885CA2 3067/4885CA7 2780/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CA1 4882/4885CA2 4881/4885CA7 4876/4885
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CA1 1132/4885CA2 1566/4885CA7 1177/4885
US-12612420-B2 Arginase inhibitors and methods of use thereof ARG1, ARG2, ARGLU1 CA1 600/4885CA2 204/4885CA7 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.